ST Huluwa announced that the company and Guangxi Weiwei, a wholly-owned subsidiary, recently received “Drug Registration Certificates” approved and issued by the State Drug Administration for cephalopril granules, vonoracin fumarate tablets, esomeprazole magnesium enteric capsules, and concentrated solutions of magnesium, sodium, and potassium sulfate for oral administration. The company's cumulative R&D expenses for the above products were 8,525,800 yuan, 9.6274 million yuan, 10.1466 million yuan, and 2,519,500 yuan, respectively. Drug approval will enrich the product line, but sales performance is affected by policies, markets, etc., and there is uncertainty.

ST Huluwa announced that the company and Guangxi Weiwei, a wholly-owned subsidiary, recently received “Drug Registration Certificates” approved and issued by the State Drug Administration for cephalopril granules, vonoracin fumarate tablets, esomeprazole magnesium enteric capsules, and concentrated solutions of magnesium, sodium, and potassium sulfate for oral administration. The company's cumulative R&D expenses for the above products were 8,525,800 yuan, 9.6274 million yuan, 10.1466 million yuan, and 2,519,500 yuan, respectively. Drug approval will enrich the product line, but sales performance is affected by policies, markets, etc., and there is uncertainty.